Journal article
Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children
T Nolan, PC Richmond, NT Formica, K Höschler, MV Skeljo, T Stoney, J McVernon, G Hartel, DC Sawlwin, J Bennet, D Ryan, RL Basser, MC Zambon
Vaccine | Published : 2008
Abstract
Objective: Highly pathogenic avian influenza A virus (H5N1) is a leading candidate for the next influenza pandemic, and infants and children may play an important role in transmission in a pandemic. Our objective was to evaluate the safety and immunogenicity of a prototype inactivated, aluminium adjuvanted, split-virus, clade 1 H5N1 vaccine (A/Vietnam/1194/2004/NIBRG-14) in infants and children aged ≥6 months to <9 years. Methods: Healthy infants and children (N = 150) received two doses of 30 μg or 45 μg H5 HA with AlPO4 adjuvant 21 days apart. Serum samples were collected for virus microneutralisation (MN) and haemagglutination inhibition (HI) assays on Days 0, 21, and 42. Six-month antibo..
View full abstractGrants
Funding Acknowledgements
G. Hartel, N.T. Formica, D.C. Sawlwin, J. Bennet, D. Ryan and R.L. Basset are employees of CSL Limited; Parkville, VIC, Australia. M.V. Skeljo is a former employee of CSL Limited. T.M. Nolan and P.C. Richmond have received honorarium payments and travel support from CSL Limited for scientific advisory meetings on unrelated vaccine research. K. Hoschler and M.C. Zambon are employees of the Health Protection Agency, Colindale, UK, which received funding from CSL Limited to conduct the laboratory assays. All other authors have no conflict of interest.